Feb 19th 2013 - Edison Investment Research today published a report on CytRx Corporation entitled "Targeting Soft Tissue Sarcoma". In summary, the report says:
CytRx’s investment case effectively rests on the successful development and commercialisation of its lead programme, aldoxorubicin, for advanced soft tissue sarcoma (STS). Backed by a strong balance sheet, encouraging Phase I/II data, and positive FDA feedback, we expect CytRx to advance its pipeline through major value inflection points in 2013. Positive data for aldoxorubicin (STS, pancreatic cancer) and tamibarotene (lung cancer) in 2013 could drive a re-rating of CytRx shares, closing the gap between the current market cap ($65m) and our base-case valuation ($120m).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »